Clinical Trial Update: Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone [Phase 2]

View source ↗

Summary

Phase 2 trial in recurrent or refractory endometrial cancer evaluating Olaparib with Durvalumab, Cediranib with Durvalumab, Olaparib with Capivasertib, and Cedi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Adenocarcinoma
• Endometrial Cancer
• Endometrial Mixed Cell Adenocarcinoma
• Endometrial Serous Adenocarcinoma
• Endometrial Undifferentiated Carcinoma
• Endometrioid Adenocarcinoma
• Uterine Carcinosarcoma
• Uterine Corpus Carcinoma

Drugs mentioned

• Capivasertib (capivasertib)
• Cediranib (Cediranib)
• IMFINZI (DURVALUMAB)
• Lynparza (olaparib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Endometrial Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-09-23